Andrew Hindley
Belfast, NIR BT97AB, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Application of the online AML classification and risk stratification calculator in a real-world cohort of AML patients.
Journal: Irish journal of medical science
Published: August 26, 2025
The impact of JAK2V617F variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation.
Journal: British journal of haematology
Published: June 27, 2025
Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL.
Journal: HemaSphere
Published: July 11, 2024
Association between JAK2V617F variable allele frequency and risk of thrombotic events in patients with myeloproliferative neoplasms.
Journal: Irish journal of medical science
Published: May 30, 2024
Nanoencapsulation of MDM2 Inhibitor RG7388 and Class-I HDAC Inhibitor Entinostat Enhances their Therapeutic Potential Through Synergistic Antitumor Effects and Reduction of Systemic Toxicity.
Journal: Molecular pharmaceutics
Published: February 09, 2024
CALR type 1 mutations are associated with an increased incidence of myelofibrosis in young male patients.
Journal: Irish journal of medical science
Published: March 31, 2022
Significance of NPM1 Gene Mutations in AML.
Journal: International journal of molecular sciences
Published: July 29, 2021
Mutational profiling in suspected triple-negative essential thrombocythaemia using targeted next-generation sequencing in a real-world cohort.
Journal: Journal of clinical pathology
Published: March 13, 2020
A molecular diagnostic algorithm for JAK2 V617F investigations in suspected myeloproliferative neoplasms.
Journal: Irish journal of medical science
Published: April 30, 2019
Showing 1-9 of 9
Last Updated: 09/26/2026